635

## NO DRAWINGS

(21) Application No. 47070/68 (2)

(22) Filed 3 Oct. 1968

(31) Convention Application No. 680349

(32) Filed 3 Nov. 1967 in

(33) United States of America (US)

(45) Complete Specification published 19 Aug. 1970

(51) International Classification A 61 k 7/00

(52) Index at acceptance A5B 771

## (54) POLYPEPTIDE LOTION

(71) We, LUZIER INCORPORATED, a Corporation organized under the laws of the State of Delaware, United States of America, of 3216 Gillham Plaza, Box 496 Kansas City, State of Missouri, United States of America, do hereby declare the invention, for which we pray that a patent may be granted to us, and the method by which it is to be performed, to be particularly described in and by the following statement:—

This invention relates to stable skin care emulsions. More particularly, it relates to stable skin care oil-in-water emulsions containing water-soluble polypeptides.

It has long been recognized that protein hydrolyzates have a beneficial effect on the skin, and as a consequence, they have been incorporated in skin creams and louions. However, to be useful in cosmetics of this character, they have to be in a water-soluble form and ordinarily appear in the aqueous phase of the composition.

It is also known that a number of other ingredients are advantageously included in skin care preparations which tend to improve the skin. These are exemplified by such materials as mineral oil, lanolin or acetylated lanolin alcohol, refined wax squalane (hexamethyltetracosane), which tend to be hydrophobic in character. Since it is advantageous to add the benefits to the skin contributed by these materials to the benefits of an aqueous solution of protein hy-drolyzates, attempts are made to incorporate them in the protein solutions. This is usually accomplished through the use of an emulsifier which forms an oil-in-water emulsion in which the hydrophobic materials constitute the oil phase.

Although, in theory compositions of the above type (i.e., oil-in-water emulsions containing the protein hydrolyzate in the water phase and the other hydrophobic skin conditioners, moisturizers, etc. in the oil phase) are very effective, as a matter of fact, there are severe limitations on these products because of their tendency to be unstable. The principal difficulty is that these compositions have been very difficult to preserve. This had resulted in the growth of organisms in the

composition which caused a coalescence of the emulsion.

Various attempts have been made to overcome this problem, all of which have left something to be desired. Thus, for example, the use of a combination of methyl - p - hydroxybenzoate, propyl p - hydroxybenzoate and benzalkanium chloride has been tried. However, these did not lead to a stable system; the system must also contain an anionic surfactant to be stable. Similarly, a combination of methyl p-hydroxybenzoate, propyl p - hydroxybenzoate and 6 - ethoxy - 2.4 - dimethyl - n - dioxane has also been tried. This, however, was unacceptable in that it darkened the products.

Studies also tended to indicate that cosmetic formulations containing water-soluble polypepuides should be preserved at the lowest possible acceptable pH. This placed a severe limitation on ingredients which could be incorporated in compositions of this character which would tend to raise the pH.

It has now been found that oil-in-water emulsions containing protein hydrolyzates in the water phase and hydrophobic materials in the oil phase may be very effectively preserved and thus stabilized by using as a preservative a combination of methyl phydroxybenzoate, propyl phydroxybenzoate and sodium ethylmercurithio - salicylate. This system is effective in the presence of anionic surfac-

tants (e.g., sodium lauryl sulfate). Fur-

thermore, it is effective in a pH range up to

about 8.5 and causes no apparent darkening or oxidation of the product.

It is therefore an object of the present invention to provide a stable oil-in-water emulsion containing water-soluble polypeptides which is stable under the influence of temperature, time and normal storage

conditions.

It is a further object of the present invention to provide a composition set out in the above object which will serve as a skin care composition capable of enhancing the absorption of water and polypeptide by the

60

55

65

70

75

80

85

90

,,

95

100

[Price 5s. 0d. (25p)]

Yet another object of the present invention is to provide a composition of the character set out in the above objects which is capable of imparting to skin persistent velvet-smooth films.

In preparing the skin care, protein hydro-lyzate (i.e., polypeptide) oil-in-water emulsion compositions of the present invention, it is necessary to use a water-soluble polypeptide. Since these materials are watersoluble, the resulting solutions have a viscosity which is substantially identical with water. Any of a variety of water-soluble polypeptides may be used for this purpose. These will usually have a M.W. in the range of 1500 to 5000. Of particular interest are those polypeptides which contain the amino acids ordinarily found in skin. The source of these materials is usually animal skins.

Especially useful polypeptide for the purpose of the present invention are hydrolysates obtained from tanned leather. These are generally characterized as polypeptides having an average molecular weight

25 of about 2500.

20

The quantity of polypeptide that will be used in accordance with the present invention will vary, depending upon the particular type of composition that is desired. In general, however, it will constitute between 0.8% to 2% by weight of the total composition, and

preferably about 1.5% by weight.

As noted above, the composition of the present invention is an oil-in-water emulsion. The polypeptide, because of its water solubility, and because it is readily transferable to the skin from aqueous solutions, is contained substantially in the aqueous phase.

In addition to the polypeptide described above, it is advantageous to include in this composition a number of materials which are beneficial in skin care. Thus, for example, it is useful to incorporate therein squalane (i.e., hexamethyltetracosane). This ingredient acts as a liquid vehicle compatible with skin and schum. It speeds up percutaneous penetration accelerates penetration through the horny layer. It is miscible with sebum and epidermal lipids, and stimulates skin re-

spiration. The quantity of squalane that may be used in accordance with the present invention may vary somewhat. In general, it will constitute between 2 to 3% by weight of the total composition, and preferably 2.5%. This material is hydrophobic in nature. Accordingly, in the present emulsion it will constitute part of the oil phase of the

emulsion.

60

Allantoin is another material which can advantageously constitute a component of the present invention. It has been found to promote cell-proliferation and remove nectoric tissue. It protects the skin from drying out and keeps it soft by helping to keep its proper moisture content. Allamoin is proven to be available to the tissues, whether in the form of creams, lotions, or powders. Also it has been found to have a protein-dispersing

(denaturant) effect.

The quantity of allantoin which may be incorporated in the present composition may also be varied depending on the results desired. Ordinarily, it will constitute between 0.15% to 0.50% by weight of the total composition, and preferably 0.20%. Furthermore, since the allantom is hydrophilic in character, it will be contained in the aqueous phase of the composition.

In addition to the components mentioned above, there may be contained in the compositions of this invention the usual additives for skin care preparations. These may include humectants, emollients, moisturizers, fillers, bulking agents, perfumes and emulsifiers. Furthermore, they may contain medicaments, and particularly medicaments which can help heal minor cuts or

wounds.

The following are illustrations of the various additives which can be incorporated in the present invention:

(a) Humectants—glycerine, propylene gly-

col, sorbitol, polyethyleneglycol.

(b) Emollients-lanolin and its derivatives, e.g., acetylated lanolins, ethoxylated lanolin alcohols. Fatty acid alcohols and

(c) Emulsifiers — glyceryl monostearate. polyoxyethylene glycol, sorbitan sesquioleate. (d) Healing Agents—ethyl aminobenzoate,

Preferred emollients used are acetylated lanolin alcohol in a range of from 2% to 5% and sodium lauryl sulfate in the range of from 0.10% to 0.40% based on the total weight of the composition.

As noted above, an important aspect of the present invention is in the utilization of the combination of methyl p - hydroxybenzoate. propyl p - hydroxybenzoate, and sodium ethylmercurithiosalicylate as a preservative system. The quantity of the respective materials may vary somewhat. However, the usual quantities that may be employed and the preferred quantities are set out in the table below. The percent by weight indicated below is on the basis of the total composition.

	% by Wt.	% by Wt.	120
methyl-p-hydroxy- benzoate	0.08 to 0.2	0-1	
propyl-p-hydroxy- benzoate	0-03 to 0-1	0.05	125
sodium ethylmercuri- thiosalicylate	0-01 to 0-03	0-02	

Ordinarily, the propyl - p - hydroxybenzoate

ISDOCID: «GB\_\_\_\_\_\_ 12026354\_\_1\_>

70

80

95

100

105

110

115

		•	•
	will be contained in the oil phase of the present emulsion composition. The methyl - p - hydroxybenzoate and the sodium ethylmercurithiosalicylate will comprise a	Oil Phase Component Per cent by weight	55
5	As noted above, the pH of the present composition can have a value up to about 8.5. However, ordinarily, it will be in the range of	Glyceryl monostearate 2-7 Cetyl alcohol 1-5 Acctulan 2-0 Squalane 3-0	60
10	about 6.5 to 8.5, and preferably in creams having a value of about 6.8 and in lotions having a value of about 8.2.  The following examples are further il-	Propyl p-hydroxybenzoate 0-05  *Polypeptide, LSN: A water-soluble polypeptide having an average M.W. of about	
15	lustrative of the present invention. It should be understood, however, that the invention is not limited thereto.	2500 obtained from the partial hydrolysis of tanned leather.	65
	Example 1	Aqueous Phase Component Per cent	
	A stable cosmetic cream is prepared as	by Weight	
	oil-in-water emulsion having the following composition, having a pH of about 6.5-7.0.	Polypeptide LSN (water soluble) 40% aq. 2-0	70
20	Oil Phase	Sodium lauryl sulfate (USP	
	Component Per cent by Weight	Powder) 0.3 Methyl p-hydroxybenzoate 0.1	
		Sodium ethylmercurithiosalicylate 0-02	75
	Light mineral oil (Saybolt	Allantoin 0-2	
25	Viscosity 50-55) 10-0 Acetulan* 4-0	Distilled water q.s. 100	
	Stearic acid 4-0	The oil phase is added to the aqueous phase	
	Cetyl alcohol 2-0	as explained in Example 1. Allantoin is	
	Refined paraffin wax 5-0	dissolved in ten parts (relative to the	80
	Lanolin (odorless) 3.0	allamoin) by weight of water, then added	
30	Squalane 3-0	after the emulsion is formed.	
	Propyl p-hydroxybenzoate 0.05	In this stable formulation, 0.3 percent by weight of sodium lauryl sulfate (anionic) was	
	*Acetylated lanolin fraction. Pale yellow	incorporated to find out whether the product	85
	liquid d. 0.867; neutral reaction; acid No.	can be stable in the presence of anionic	0.5
	0.36; saponification No. 190-3.	detergent. Also, in this stable formulation,	
35	A avecus Dhase	0.2 percent by weight of Allantoin. The	
33	Aqueous Phase Component Per cent	incorporated in the cream to give the skin a velvet-smooth protective film. Also	00
	by Weight		90
		0.2 percent by weight of Allantion. The	
	Glycerin 2-0	emulsion was tested at 115°F, temperature	
40	Borax 0.5 Triethanolamine 0.7	and freezing temperature for a period of	
40	Polypeptide LSN (water soluble)*	365 days. No rancidity, discoloration, or separation was observed.	95
	40% aq. 4-0	soparation was costs vol.	
	Methyl p-hydroxybenzoate 0.1	,	
, -	Sodium ethylmercurithiosalicylate 0.02	WHAT WE CLAIM IS:—	
45	Allantoin 0.20	1. A stable oil-in-water skin care emulsion	
	Distilled water q.s. 100  Components of the oil phase are melted	composition containing a water-soluble poly-	
	together to 180°F. Components of the aqueous	peptide in the aqueous phase, said composi- tion containing a stabilizing amount of a	100
e-	phase are dissolved by heating to 185°F. The	preservative system comprising methyl - p	
50	oil phase is then added to the aqueous phase	- hydroxybenzoate, propyl - p -	
	with mild mixing to room temperature.	hydroxybenzoate and sodium ethyl-	
	Example 2	mercurithiosalicylate.	105
	A stable cosmetic losion prepared from the	<ol> <li>A composition according to claim 1, containing by weight of the total composi-</li> </ol>	
	following components having a pH of 8.0-8.5.	tion:	
•			

	(a) 0.08 to 0.20% methyl - p - hydroxybenzoate, (b) 0.03 to 0.10% propyl - p - hydroxybenzoate, and	containing lanolin or acetylated lanolin 25 alcohol.  9. A composition according to claim 2, wherein the polypeptide has a molecular
5	(c) 0.01 to 0.03% sodium ethylmercurithiosalicylate, and (d) 0.8% to 2% of a water-soluble polypeptide having a molecular weight in the	weight in the range of about 2500.  10. A composition according to claim 9, containing on the basis of the total weight of the composition:
10	range of from 1500 to 5000.  3. A composition according to claim 2, including from 0.15 to 0.50% by weight of allantoin and from 2% to 3% by weight of squalane.	(a) 2% to 3% squalane, (b) 2% to 5% acetylated lanolin alcohol, (c) 0.15% to 0.50% allantoin, (d) 0.10 to 0.40% sodium lauryl sulfate, (e) 0.08% to 0.20% methyl - p -
15	4. A composition according to claim 3, in which the pH is in the range of from 6.5 to 8.5.  5. A composition according to claims 1 to 4 including an anionic surfactant.	hydroxybenzoate,  (f) 0.03% to 0.1% propyl - p - hydroxybenzoate, and  (g) 0.01% to 0.03% sodium ethylmercurithiosalicylate.
20	6. A composition according to claim 5, wherein the surfactant is sodium lauryl sulfate. 7. A composition according to claim 5, including an emollient and a humectant. 8. A composition according to claim 7.	STEVENS, HEWLETT & PERKINS, Chartered Patent Agents, 5 Quality Court, Chancery Lane, London, W.C.2.

(7572) Printed by Her Majesty's Stationery Office Press, Edinburgh, 1970.

Published by The Patent Office, 25 Southampton Buildings, London, WC2A 1AY, from which copies may be obtained.

Inventor(s) E FARBER Filed: November 13, 2001 Atty Docker 69273-0013 CUSTOMER'NO. 24633 METHODS FOR TREATMENT OF INFLAMMATORY DISEASES